Abstract
Over the past years, SARS-CoV-2 has shown a worrisome tendency for immune escape mutations. Up until now, this development has culminated in the emergence of SARS-CoV-2 ‘Omicron’ variants. Indeed, monoclonal antibody drugs which had previously been effective and thus approved for COVID-19 treatment are ineffective in neutralizing the currently circulating ‘Omicron’ virus strains. This is remarkably different for polyclonal immunoglobulin (IG) preparations that are manufactured from plasma of thousands of COVID-19 convalescent and/or vaccinated donors: In the present study, it is shown that the neutralizing potency of currently released IG lots against ‘Omicron’ is still in a range for which successful treatment of COVID-19 in hospitalized (i.e., symptomatic) immunocompromised patients has been proposed. Consequentially, for a prophylactic situation – the typical setting of immunodeficient patients receiving periodic IG infusions –, it can be anticipated that the effectiveness of current IG lots is even more promising.
References
Downloads
pdf
Authors
David McIntosh UK Plasma Action, Petersfield, United Kingdom
Thierry Burnouf
UK Plasma Action, Petersfield, United Kingdom; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
Michael Karbiener
Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria
Maria R. Farcet
Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria
Thomas R. Kreil
Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria
- Abstract viewed - 1331 times
- pdf downloaded - 0 times